Efficacy and safety of switching other tyrosine kinase inhibitors to regorafenib combined with primary PD-1 antibodies in patients with hepatocellular carcinoma.
- Resource Type
- Article
- Source
- Journal of Clinical Oncology; 2023 Supplement 16, Vol. 41, pe14612-e14612, 1p
- Subject
- Language
- ISSN
- 0732183X